

A Customer-Centric, Innovative and Reliable CDMO with Global Solutions



DS

Minhang, Shanghai R&D Center

- Area: 20,000 m²
- For Mg-kg Scale Preparation, Process Development and Quality Research
- HP Area: Achieved OEB 5 (OEL <0.05 µg/m³)



DS DP

Pudong, Shanghai Biologics R&D and Manufacturing

- Antibody (200-500 L)
- Bioconjugation (10-200 L, OEB 5)
- Pre-clinical to Phase II
- Antibody (500-2,000 L)
- Bioconjugation (200-500 L, OEB 5)
- Phase II to Commercial



DS

Fengxian, Shanghai GMP Manufacturing

- Area: 64,000 m²
- IND, GMP Clinical Batches and Commercial Manufacturing
- HP Area: Achieved OEB 5 (OEL <0.05 µg/m³)



DP

Beibei, Chongqing GMP Manufacturing

- 6 Drug Product GMP Workshops
- Liquid Injection: 25 M units/year
- Lyophilized Powder: 3.3 M units/year



Early Stage
Development Services



Process Development
and DS Manufacturing



Formulation
Development and DP
Manufacturing



Analytical
Development and QC



Registration Services

Operational
Excellence

IP

QA

EHS

RA

PM

Supply Chain

Global Site
Compliance



Tides

With R&D platforms including peptides, oligonucleotides, conjugated drugs, high performance liquid chromatography, and Tides analysis, the Porton Tides CDMO Services Platform is committed to providing integrated CMC solutions for global customers, covering all types of new drugs from pre-clinical to commercial.



Peptides

- Linear Peptides (<50 aa)
- Cyclic Peptides (<50 aa)
- Peptide Modifications
- Key RSMs and Intermediates



Oligonucleotides

- ASO, siRNA
- PMO
- Aptamer
- sgRNA
- Oligo Modifications



Conjugates

- Small Molecule Drug Conjugate
- PDC
- ADC Payload-Linker
- XDC (RDC, Precursors)



Drug Delivery Materials

- Ionizable Lipids / Cationic Lipids
- Polymers for Drug Delivery
- Complex/Conjugate Polysaccharides
- Other Lipids



Sterile Formulations

- Lyophilized Product
- Liquid Product
- Prefilled Syringe
- Auto-injectors



Complex Injection

- LNP
- Exosome
- Microspheres
- Nano-drug Carriers